Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $52.00. The company’s shares closed yesterday at $53.96.

According to the Microsoft Gaming CEO, no games are off limits, including titles from the Halo series. Microsoft has been ...

Halozyme Therapeutics shares are trading lower after the company announced a proposal to combine with Evotec.

The $2B-plus Intuit Dome features an array of boundary-pushing fan experience aspects, but its Halo Board, the largest double-sided videoboard in an arena ever, may have the biggest impact on the ...

At close: November 15 at 3:00 PM EST ...

Star Wars Episode VI: Return Of The Jedi has had its rating upgraded from a U to a PG because of its violence and a scene showing Han Solo frozen in carbonite. The film was given a U "universal ...

HIGH SCHOOL TONIGHT. SARAH. YEAH. TEACHERS ARE CURRENTLY WORKING UNDER THEIR OLD CONTRACTS HERE AT HEMPFIELD. BUT THAT SOON COULD CHANGE WITH THIS NEW TENTATIVE AGREEMENT ON THE TABLE. I’M ALL ...

Macquarie analyst Paul Golding has maintained their bullish stance on LYV stock, giving a Buy rating yesterday ... that allow businesses to reach customers through concerts, venue, festivals ...

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage ...